There are hundreds of cell types in the human body, each with a specific role spelled out in their DNA. In theory, all it ...

The partners are launching ImmuneScape, a multiomics program using spatial and single-cell sequencing to study immune drivers ...

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

When Jorie Kraus was diagnosed with an incurable rare disease, two young researchers created an AI tool to find a treatment.

Scientists are searching for therapeutics that mimic the life-extending benefits of caloric restriction, exercise, and a good ...

Using CLASSIC, Rice researchers realized that circuits are variable, having multiple pathways to elicit the same outcome.

Tryptophan does far more than help us sleep—it fuels brain chemistry, energy production, and mood-regulating ...

REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative year ...

Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase 1 ...

Exploring eQTL studies as a cornerstone in deciphering the genetic architecture of gene regulation Understanding the genetic ...